Cargando…

N(6)‐methyladenosine (m(6)A) RNA modification in human cancer

N(6)‐methyladenosine (m(6)A) RNA modification, first discovered in 1974, is the most prevalent, abundant and penetrating messenger RNA (mRNA) modification in eukaryotes. This governs the fate of modified transcripts, regulates RNA metabolism and biological processes, and participates in pathogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Fu‐Chun, Zhu, Zhi‐Man, Pei, Dong‐Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653258/
https://www.ncbi.nlm.nih.gov/pubmed/33029866
http://dx.doi.org/10.1111/cpr.12921
_version_ 1783607867544174592
author Huo, Fu‐Chun
Zhu, Zhi‐Man
Pei, Dong‐Sheng
author_facet Huo, Fu‐Chun
Zhu, Zhi‐Man
Pei, Dong‐Sheng
author_sort Huo, Fu‐Chun
collection PubMed
description N(6)‐methyladenosine (m(6)A) RNA modification, first discovered in 1974, is the most prevalent, abundant and penetrating messenger RNA (mRNA) modification in eukaryotes. This governs the fate of modified transcripts, regulates RNA metabolism and biological processes, and participates in pathogenesis of numerous human diseases, especially in cancer through the reciprocal regulation of m(6)A methyltransferases (“writers”) and demethylases (“erasers”) and the binding proteins decoding m(6)A methylation (“readers”). Accumulating evidence indicates a complicated regulation network of m(6)A modification involving multiple m(6)A‐associated regulatory proteins whose biological functions have been further analysed. This review aimed to summarize the current knowledge on the potential significance and molecular mechanisms of m(6)A RNA modification in the initiation and progression of cancer.
format Online
Article
Text
id pubmed-7653258
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76532582020-11-16 N(6)‐methyladenosine (m(6)A) RNA modification in human cancer Huo, Fu‐Chun Zhu, Zhi‐Man Pei, Dong‐Sheng Cell Prolif Reviews N(6)‐methyladenosine (m(6)A) RNA modification, first discovered in 1974, is the most prevalent, abundant and penetrating messenger RNA (mRNA) modification in eukaryotes. This governs the fate of modified transcripts, regulates RNA metabolism and biological processes, and participates in pathogenesis of numerous human diseases, especially in cancer through the reciprocal regulation of m(6)A methyltransferases (“writers”) and demethylases (“erasers”) and the binding proteins decoding m(6)A methylation (“readers”). Accumulating evidence indicates a complicated regulation network of m(6)A modification involving multiple m(6)A‐associated regulatory proteins whose biological functions have been further analysed. This review aimed to summarize the current knowledge on the potential significance and molecular mechanisms of m(6)A RNA modification in the initiation and progression of cancer. John Wiley and Sons Inc. 2020-10-07 /pmc/articles/PMC7653258/ /pubmed/33029866 http://dx.doi.org/10.1111/cpr.12921 Text en © 2020 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Huo, Fu‐Chun
Zhu, Zhi‐Man
Pei, Dong‐Sheng
N(6)‐methyladenosine (m(6)A) RNA modification in human cancer
title N(6)‐methyladenosine (m(6)A) RNA modification in human cancer
title_full N(6)‐methyladenosine (m(6)A) RNA modification in human cancer
title_fullStr N(6)‐methyladenosine (m(6)A) RNA modification in human cancer
title_full_unstemmed N(6)‐methyladenosine (m(6)A) RNA modification in human cancer
title_short N(6)‐methyladenosine (m(6)A) RNA modification in human cancer
title_sort n(6)‐methyladenosine (m(6)a) rna modification in human cancer
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653258/
https://www.ncbi.nlm.nih.gov/pubmed/33029866
http://dx.doi.org/10.1111/cpr.12921
work_keys_str_mv AT huofuchun n6methyladenosinem6arnamodificationinhumancancer
AT zhuzhiman n6methyladenosinem6arnamodificationinhumancancer
AT peidongsheng n6methyladenosinem6arnamodificationinhumancancer